Universal Health Services reports second-quarter results on July 27 against a backdrop where the central debate — how quickly behavioral health volumes accelerate — remains unresolved, and where options traders have shifted sharply toward the bullish side ahead of the release.
The most striking signal heading into the print is in options positioning, and it cuts against the cautious tone that has defined UHS for most of 2026. The put/call ratio has dropped to 0.52, nearly two standard deviations below its 20-day average of 0.74 — the most call-heavy reading in recent months. That represents a significant reversal from mid-July, when the PCR was running above 0.90 and traders were hedging more aggressively. The stock has responded in kind, up 7% over the past month to $155.75, with a 3% gain on the week alone. Short interest of 5.5% of the free float is modest enough not to dominate the story — it crept up roughly 4% over the past month but remains well below squeeze territory, and borrow availability at roughly 13x current short interest is exceptionally loose, with borrowing costs at just 0.43%.
The bull-bear divide is squarely about execution speed. Bulls point to UHS's dominant position in behavioral health, where patient volumes are structurally growing, and to a valuation that looks genuinely cheap — the stock trades near 6.2x trailing earnings and just over 5.2x EV/EBITDA, with analysts still holding a consensus target well above the current price. Guggenheim trimmed its target to $195 on July 20 while keeping a Buy, and TD Cowen lowered to $197 in June — both firms still see 25-30% upside from here but are clearly more cautious on timing. Barclays delivered the sharpest signal, downgrading to Equal-Weight on July 8, citing a heavier ramp path for new behavioral assets than previously modeled. Bears lean on that ramp narrative hard: Q1 core EBITDA fell 4% against management's stated 5% growth target, labor costs remain elevated, and the elongated path to 2-3% behavioral volume growth raises questions about whether the current multiple is justified. The EV/EBIT factor score sits at the 96th percentile of the universe, meaning value looks compelling in isolation — but forward earnings momentum ranks in just the 8th percentile, a reminder that cheap multiples reflect genuine uncertainty about when growth reaccelerates.
Peer context adds one notable data point. Tenet Healthcare jumped 17% on Thursday and is up nearly 20% on the week — an outlier move that may be drawing some attention toward the hospital sector broadly heading into UHS's own print. HCA Healthcare was up around 3% on the week, more in line with UHS's own performance.
Sunday's earnings release will test whether Q2 delivered the behavioral volume inflection management has been promising, or whether the ramp remains stubbornly slow — the answer to that question is what separates a $155 stock from the $195-$205 range where most of the Street still thinks it belongs.
See the live data behind this article on ORTEX.
Open UHS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
